City Therapeutics
Updated: June 09, 2026
CEO - John Maraganore
Country: USA | Funding: $234.5M (+)
Founded: 2024
Website: https://www.citytx.com/
City Therapeutics is focused on developing next-generation small interfering RNAs. Its lead candidate, CITY-FXI, is a potential best-in-class RNA interference-based therapeutic that targets a clotting factor. It can help prevent blood clots and serious conditions such as stroke, deep vein thrombosis (DVT), and myocardial infarction. By targeting a key protein called factor XI, CITY-FXI aims to protect patients from thrombosis while reducing the risk of bleeding. Another candidate, CITY-RBP4, is a promising RNA interference-based therapeutic for preventing vision loss in Stargardt disease.
Founded: 2024
Website: https://www.citytx.com/
City Therapeutics is focused on developing next-generation small interfering RNAs. Its lead candidate, CITY-FXI, is a potential best-in-class RNA interference-based therapeutic that targets a clotting factor. It can help prevent blood clots and serious conditions such as stroke, deep vein thrombosis (DVT), and myocardial infarction. By targeting a key protein called factor XI, CITY-FXI aims to protect patients from thrombosis while reducing the risk of bleeding. Another candidate, CITY-RBP4, is a promising RNA interference-based therapeutic for preventing vision loss in Stargardt disease.
